New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene ...
MIAMI, FLORIDA (EMBARGOED UNTIL MAY 25, 2023, AT 5 P.M. ET) – An early-phase study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine ...
Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...
Hosted on MSN
Small molecule inhibitors restore normal BRAF structure, offering insight into cancer-causing mutations
An altered structure that 'mimics' the active form of BRAF Around half of all cancers are associated with dysfunction of the MAPK pathway, a communication system that enables cells to integrate ...
BRAF is the most commonly mutated gene associated with melanoma, found in more than 50 percent of patients. The gene encodes a cytoplasmic kinase that is a member of the MAPK signal-transduction ...
New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene ...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results